CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Drug absorption

Can you accurately predict how much drug absorbs into the bloodstream?


Drug absorption can be affected by both drug-specific and patient-specific factors. Absorption data determines how much of the drug reaches the systemic circulation after oral or inhaled administration so that a suitable therapeutic range can be established.

Due to their physiological complexity, recreating human-representative biological barriers in vitro is difficult. Animals offer limited advantages as their biological make-up differs from humans. Combined, this means accurately predicting drug absorption and permeability in preclinical drug development can be challenging.

Inhaled medicines offer an advantage over oral administration, due to the low metabolic capacity of the lung. Unfortunately, there are relatively few in vitro inhaled drug absorption assays available. In vitro gut absorption models suffer from low metabolic capacity, which limits their ability to accurately mimic the human intestinal response to orally administered drugs. Both suffer from permeability values that are not physiologically relevant.

Our solution

PhysioMimix™ Drug Absorption Assays utilize Lung-on-a-chip (alveolar or bronchial), or Gut-on-a-chip co-culture models. Fundamental to the success of these models is organ-specific perfusion, which drives the development of complex 3D tissue morphologies, the expression of key cellular components (e.g., mucus or metabolic enzymes), and barrier integrities that align closely with the human.

These models can be used to calculate absorption into cells and/or drug permeability rates across the epithelial barrier. The oral drug absorption assay can also predict systemic exposure following oral dosing via the first-pass metabolism. Data derived using these assays more accurately translates into human outcomes compared to traditional approaches.

Drug absorption cells

Studying drug absorption

Limitations with current techniques

  • Difficult to predict transport rates for slowly absorbed compounds
  • Lack of mucous secretion
  • Limited transporter expression/activity
  • Low metabolic activity
  • In vivo model data fail to translate into clinical studies

Advancements with PhysioMimix OOC

  • Perfusion of microtissues increases in-vivo-like barrier integrity and permeability of the epithelium
  • Goblet cells secrete mucus, more closely mimicking the mucosal barrier
  • Major transporters are expressed by the epithelium
  • Organ-relevant metabolic capacity
  • Specific tissue functions and assay types are enabled by the 3D complexity of the model

​

​

Organ-specific perfusion delivers physiologically relevant barrier integrities


Perfused Gut-on-a-chip models provide an order of magnitude smaller TEER values than standard 2D static Caco-2 cell cultures to better predict the permeabilities of drugs with varying rates of absorption.

Gut-on-a-chip model graph
Gut-on-a-chip model graph

​

​

Overcoming the issue of predicting inhaled drug ADME in vitro


Measure the permeability and cellular accumulation of inhaled medications using human Lung-on-a-chip models, with compounds dosed onto the epithelial airway interface.

ADME data table
ADME bar graphs

Access our ADME service


Get instant access to PhysioMimix Drug Absorption Assays via our CRO Service. Through a collaborative approach, our experts work with you to plan and execute your study.

Bespoke projects are carried out by our dedicated team of scientists in our CRO facility providing you with actionable data within weeks.

Learn more

Add PhysioMimix OOC into your lab


Harness the power of PhysioMimix OOC in your own lab with the purchase of a single- or multi-organ microphysiological system.

With a growing community of users and support from our experts, there has never been a better time to transition into 3D cell culture.

Learn more

Featured resources

Webinars

web s2e4 |

Engineering Mucosal Barriers

Application notes

Predicting PermEability MPS graphic |

Predicting human drug permeability with a gut microphysiological system

Posters

cnb649 elrig dd 22 poster |

Evaluation of in vitro human alveolar and bronchial microphysiological systems to predict the permeability and absorption of inhaled pulmonary medications

View all Drug absorption related resources

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023